Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
clinical trials
6
×
life sciences
national blog main
alnylam pharmaceuticals
boston top stories
drugs
rna interference
boston
new york blog main
new york top stories
patisiran
akcea therapeutics
fda
inotersen
national top stories
onpattro
san diego blog main
san diego top stories
tafamidis
aminolevulinic acid
biotech
givosiran
hereditary transthyretin amyloidosis
new york
pfizer
regeneron pharmaceuticals
san francisco blog main
san francisco top stories
vyndaqel
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
alirocumab
amgen
andrew fire
anylam pharmaceuticals
barry greene
boston university
What
alnylam
6
×
drug
fda
medicine
pharmaceuticals
rna
ago
rnai
approved
data
interference
medicines
new
ok
patients
second
seek
speedy
afternoon
akcea
alnylam’s
amyloidosis
approval
approve
attr
available
awaits
based
battle
biological
cholesterol
cleared
crossed
debilitating
decades
decision
discovered
disease
evidence
far
Language
Current search:
alnylam
×
" clinical trials "
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision